成都苑东生物制药股份有限公司2025年度业绩快报公告

Financial Performance Summary - The company reported total operating revenue of 1,331.40 million yuan for the year 2025, a decrease of 1.36% year-on-year [1] - The net profit attributable to the parent company was 283.25 million yuan, an increase of 18.89% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 206.24 million yuan, up 18.01% year-on-year [1] Asset and Equity Growth - As of the end of the reporting period, total assets reached 3,798.86 million yuan, an increase of 11.73% from the beginning of the period [2] - The equity attributable to the parent company was 2,932.03 million yuan, reflecting an increase of 8.68% from the beginning of the period [2] Operational Challenges and Strategies - The slight decline in total operating revenue was influenced by the implementation of the tenth batch of national centralized procurement [2] - The company adopted multiple measures such as optimizing revenue structure, enhancing cost control, and improving operational efficiency to mitigate the adverse effects of the procurement policy, resulting in stable profit growth [2]